Shin S, Kim H, Ko M, Park S, Park J, Kim S
Front Microbiol. 2025; 16:1502630.
PMID: 40046304
PMC: 11880001.
DOI: 10.3389/fmicb.2025.1502630.
Zhou M, Xiao H, Yang X, Cheng T, Yuan L, Xia N
MedComm (2020). 2025; 6(2):e70056.
PMID: 39830020
PMC: 11739453.
DOI: 10.1002/mco2.70056.
Qiao K, Liu L, Chen Y, Huang Q, Chen B, Wu J
Front Nutr. 2025; 11():1525768.
PMID: 39811675
PMC: 11730078.
DOI: 10.3389/fnut.2024.1525768.
Wu L, Xu W, Jiang H, Yang M, Cun D
Acta Pharm Sin B. 2025; 14(12):5132-5160.
PMID: 39807330
PMC: 11725141.
DOI: 10.1016/j.apsb.2024.08.026.
Vasquez R, Song J, Mendoza R, Hwang I, Bagon B, Engstrand L
Microb Biotechnol. 2025; 18(1):e70073.
PMID: 39797809
PMC: 11724470.
DOI: 10.1111/1751-7915.70073.
Mucosal immunization with the lung Lactobacillus-derived amphiphilic exopolysaccharide adjuvanted recombinant vaccine improved protection against P. aeruginosa infection.
Zhang H, Sheng S, Li C, Bao X, Zhao L, Chen J
PLoS Pathog. 2024; 20(11):e1012696.
PMID: 39556597
PMC: 11611261.
DOI: 10.1371/journal.ppat.1012696.
Different immunogens and prime-boost vaccination strategies affect the efficacy of recombinant candidate vaccines against pathogenic orthopoxviruses.
Radaelli A, Zanotto C, Brambilla C, Adami T, Paolini F, Venuti A
Virol J. 2024; 21(1):282.
PMID: 39511612
PMC: 11542223.
DOI: 10.1186/s12985-024-02534-4.
Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination.
Liu S, Wen Y, Shan X, Ma X, Yang C, Cheng X
Nat Commun. 2024; 15(1):9471.
PMID: 39488531
PMC: 11531489.
DOI: 10.1038/s41467-024-53914-x.
Formulation Attributes Impact Immune Profile of an Oral and Thermostable COVID-19 Subunit Vaccine.
Burlet E, Thomas N, Carwell S, Gershman B, Morefield G
Vaccines (Basel). 2024; 12(10).
PMID: 39460254
PMC: 11511547.
DOI: 10.3390/vaccines12101087.
Immunoinformatics Design of a Multiepitope Vaccine (MEV) Targeting : A Novel Computational Approach.
Naorem R, Pangabam B, Bora S, Fekete C, Teli A
Pathogens. 2024; 13(10).
PMID: 39452787
PMC: 11509883.
DOI: 10.3390/pathogens13100916.
Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake.
Seefeld M, Templeton E, Lehtinen J, Sinclair N, Yadav D, Hartwell B
Front Immunol. 2024; 15:1419527.
PMID: 39286244
PMC: 11403286.
DOI: 10.3389/fimmu.2024.1419527.
Vaccines for Respiratory Viruses-COVID and Beyond.
Rajanala K, Upadhyay A
Vaccines (Basel). 2024; 12(8).
PMID: 39204059
PMC: 11360283.
DOI: 10.3390/vaccines12080936.
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges.
Bai Z, Wan D, Lan T, Hong W, Dong H, Wei Y
ACS Nano. 2024; 18(36):24650-24681.
PMID: 39185745
PMC: 11394369.
DOI: 10.1021/acsnano.3c10797.
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine.
Cowling B, Okoli G
Drugs. 2024; 84(9):1013-1023.
PMID: 39167316
PMC: 11438668.
DOI: 10.1007/s40265-024-02083-8.
Engineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A virus in mice.
Huang L, Tang W, He L, Li M, Lin X, Hu A
Nat Commun. 2024; 15(1):6802.
PMID: 39122688
PMC: 11315933.
DOI: 10.1038/s41467-024-51182-3.
Induction of protective immune responses at respiratory mucosal sites.
Park S, Wiest M, Yan V, Wong P, Schotsaert M
Hum Vaccin Immunother. 2024; 20(1):2368288.
PMID: 38953250
PMC: 11221474.
DOI: 10.1080/21645515.2024.2368288.
mRNA Technology and Mucosal Immunization.
Toniolo A, Maccari G, Camussi G
Vaccines (Basel). 2024; 12(6).
PMID: 38932399
PMC: 11209623.
DOI: 10.3390/vaccines12060670.
Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy.
Bouazzaoui A, Abdellatif A
Vaccine X. 2024; 19:100500.
PMID: 38873639
PMC: 11170481.
DOI: 10.1016/j.jvacx.2024.100500.
Sex-biased immunogenicity of a mucosal subunit vaccine against SARS-CoV-2 in mice.
Li J, Hsu K, Howe S, Hoang T, Xia Z, Berzofsky J
Front Immunol. 2024; 15:1386243.
PMID: 38835757
PMC: 11148259.
DOI: 10.3389/fimmu.2024.1386243.
The application of plant-exosome-like nanovesicles as improved drug delivery systems for cancer vaccines.
Hillman T
Discov Oncol. 2024; 15(1):136.
PMID: 38683256
PMC: 11058161.
DOI: 10.1007/s12672-024-00974-6.